Orelabrutinib

Min.Order / FOB Price:Get Latest Price

0	Negotiable

Product Details
Company Profile

Min.Order :0
Purity: 95%

Keywords

ICP-022 ICP 022

Quick Details

Appearance:
Application:For research use only.
PackAge:
ProductionCapacity:
Storage:
Transportation:

Superiority:

We provide customized and high-quality Orelabrutinib product for your project.

Details:

Orelabrutinib is an orally administered, potent, irreversible and highly selective BTK inhibitor. In December 2020, orelabrutinib received its first approval in China for the treatment of patients with mantle cell lymphoma (MCL) or chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL).

View All